Brooke Wietharn
The University of Kansas Cancer Center(US)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Hepatitis C virus research, Liver Disease Diagnosis and Treatment
Most-Cited Works
- → Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study(2022)219 cited
- → Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study(2022)102 cited
- → Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours(2023)57 cited
- → Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma(2022)36 cited
- → A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma(2023)22 cited
- → Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma(2023)21 cited
- → Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors(2023)13 cited
- → OS-112-YI Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapybased systemic therapy(2024)4 cited
- → The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab(2023)3 cited